These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Severe hypertension after ingestion of an appetite suppressant (phenylpropanolamine) with indomethacin. Lee KY; Beilin LJ; Vandongen R Lancet; 1979 May; 1(8126):1110-1. PubMed ID: 86834 [TBL] [Abstract][Full Text] [Related]
4. Phenylpropanolamine and hemorrhagic stroke. Ernst ME; Hartz A N Engl J Med; 2001 Apr; 344(14):1094; author reply 1095. PubMed ID: 11291667 [No Abstract] [Full Text] [Related]
5. [Stroke and phenylpropanolamine: what risk factors and what recommendations in request?]. Die-Kacou H; Kamagaté M; Daubrey-Potey TH; Bamba-Kamagaté D; Yavo JC; Balayssac E; Gboignon VM; Kakou KA; Gilbernaire AF Dakar Med; 2007; 52(1):56-7. PubMed ID: 19102094 [No Abstract] [Full Text] [Related]
6. Effects of sustained-release oral phenylpropanolamine on the nasal mucosa of healthy subjects. Graf P; Toll K; Palm J; Hallén H Acta Otolaryngol; 1999; 119(7):837-42. PubMed ID: 10687944 [TBL] [Abstract][Full Text] [Related]
8. A double dose of phenylpropanolamine causes transient hypertension. Lake CR; Zaloga G; Clymer R; Quirk RM; Chernow B Am J Med; 1988 Sep; 85(3):339-43. PubMed ID: 3414729 [TBL] [Abstract][Full Text] [Related]
9. FDA issues public health advisory on phenylpropanolamine in drug products. Meadows M FDA Consum; 2001; 35(1):9. PubMed ID: 11930934 [No Abstract] [Full Text] [Related]
10. Phenylpropanolamine-associated hypertension after the use of "over-the-counter" appetite-suppressant products. McEwen J Med J Aust; 1983 Jul; 2(2):71-3. PubMed ID: 6679050 [TBL] [Abstract][Full Text] [Related]
11. Transient hypertension after two phenylpropanolamine diet aids and the effects of caffeine: a placebo-controlled follow-up study. Lake CR; Zaloga G; Bray J; Rosenberg D; Chernow B Am J Med; 1989 Apr; 86(4):427-32. PubMed ID: 2929629 [TBL] [Abstract][Full Text] [Related]
12. Phenylpropanolamine and blood pressure: a review of prospective studies. Morgan JP; Funderburk FR Am J Clin Nutr; 1992 Jan; 55(1 Suppl):206S-210S. PubMed ID: 1728835 [TBL] [Abstract][Full Text] [Related]
13. Neurological and cardiac events on phenylpropanolamine. Prescrire Int; 1999 Dec; 8(44):181. PubMed ID: 11503819 [TBL] [Abstract][Full Text] [Related]
14. A double-blind, placebo-controlled trial of decongestant-antihistamine for the treatment of sinusitis in children. McCormick DP; John SD; Swischuk LE; Uchida T Clin Pediatr (Phila); 1996 Sep; 35(9):457-60. PubMed ID: 8877243 [TBL] [Abstract][Full Text] [Related]
15. Three controlled trials of weight loss with phenylpropanolamine. Altschuler S; Conte A; Sebok M; Marlin RL; Winick C Int J Obes; 1982; 6(6):549-56. PubMed ID: 6761288 [TBL] [Abstract][Full Text] [Related]
16. Regarding "phenylpropanolamine and hemorrhagic stroke in the hemorrhagic stroke project". Clapp R; Williams ML Ann Epidemiol; 2006 Jul; 16(7):580-2; author reply 586. PubMed ID: 16814149 [No Abstract] [Full Text] [Related]
17. [Do we practice too uncritical prescription of phenylpropanolamine?]. Lischner B Lakartidningen; 2008 Aug 6-19; 105(32-33):2190. PubMed ID: 18780697 [No Abstract] [Full Text] [Related]
19. Regulatory decisions in a globalised world: the domino effect of phenylpropanolamine withdrawal in Latin America. Figueras A; Laporte JR Drug Saf; 2002; 25(10):689-93. PubMed ID: 12167064 [TBL] [Abstract][Full Text] [Related]
20. Regarding "Phenylpropanolamine and hemorrhagic stroke in the hemorrhagic stroke project": mercenary epidemiology--data reanalysis and reinterpretation for sponsors with financial interest in the outcome. Michaels D Ann Epidemiol; 2006 Jul; 16(7):583-5; author reply 586. PubMed ID: 16814150 [No Abstract] [Full Text] [Related] [Next] [New Search]